“…Spans M8 to M10 show relatively small changes in the known conformations and may 1 Abbreviations: srCa ATPase, sarcoplasmic reticulum Ca 2+ -ATPase; omeprazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; protein-bound form of pantoprazole, [1-(5-difluoromethoxy-1H-benzimidazol-2-yl)-3,4-dimethoxypridinium-2-yl]methyldisulfidyl protein; SCH28080, 3-cyanomethyl-2-methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine; Byk99, (7R,8R,9R)-7,8-dihydroxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2- Considerable effort in the past decade utilizing several site-directed mutations and analysis of chimeras has supported many other structure-function generalizations for the P 2 -type ATPases (2,26,27). The rearrangement of the three cytoplasmic domains in the E 1 to E 2 transition and the associated changes in the orientation of the membrane helices implied by the various srCa ATPase crystal structures are believed to be generally conserved (28,29). This assumption has provided the foundation of structure-function analyses for the potassium counter-transport ATPases (12,26,30,31).…”